PE20140570A1 - Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos - Google Patents
Pirrolotriazinas sustituidas con hidroximetilarilo y sus usosInfo
- Publication number
- PE20140570A1 PE20140570A1 PE2013002774A PE2013002774A PE20140570A1 PE 20140570 A1 PE20140570 A1 PE 20140570A1 PE 2013002774 A PE2013002774 A PE 2013002774A PE 2013002774 A PE2013002774 A PE 2013002774A PE 20140570 A1 PE20140570 A1 PE 20140570A1
- Authority
- PE
- Peru
- Prior art keywords
- triazin
- methanol
- amino
- pyrrolotriazines
- compounds
- Prior art date
Links
- 150000003921 pyrrolotriazines Chemical group 0.000 title abstract 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000005590 Choroidal Neovascularization Diseases 0.000 abstract 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 2
- 102000018918 Activin Receptors Human genes 0.000 abstract 1
- 108010052946 Activin Receptors Proteins 0.000 abstract 1
- 101100490437 Mus musculus Acvrl1 gene Proteins 0.000 abstract 1
- 206010030113 Oedema Diseases 0.000 abstract 1
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 abstract 1
- 208000017442 Retinal disease Diseases 0.000 abstract 1
- 206010038923 Retinopathy Diseases 0.000 abstract 1
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 1
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical class C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE PIRROLOTRIAZINAS DE FORMULA (I) DONDE A ES N O CR2, EN DONDE R2 ES H, F O Cl; R1 ES H, F, METILO, ETILO, ENTRE OTROS; Z ES ALQUILO(C1-C4), CICLOALQUILO(C3-C6), ENTRE OTROS. SON COMPUESTOS PREFERIDOS: [4-(4-AMINO-7-PROPILPIRROLO[2,1-f][1,2,4]TRIAZIN-5-IL)FENIL]METANOL; [4-(4-AMINO-7-PROPILPIRROLO[2,1-f][1,2,4]TRIAZIN-5-IL)-2,6-DIFLUOROFENIL]METANOL; {4-AMINO-5-[3,5-DIFLUORO-4-(HIDROXIMETIL)FENIL]PIRROLO[2,1-f][1,2,4]TRIAZIN-7-IL}-(CICLOPROPIL)METANOL; ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DEL RECEPTOR DE ACTIVINA TIPO QUINASA-1 (ALK1) SIENDO UTILES EN EL TRATAMIENTO DE DEGENERACION MACULAR RELACIONADA CON LA EDAD (DME), NEOVASCULARIZACION COROIDEA (NVC), RETINOPATIA DIABETICA, EDEMA MACULAR DIABETICO (EMD)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161503840P | 2011-07-01 | 2011-07-01 | |
| EP12161547 | 2012-03-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20140570A1 true PE20140570A1 (es) | 2014-04-28 |
Family
ID=47436537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2013002774A PE20140570A1 (es) | 2011-07-01 | 2012-06-26 | Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US9040691B2 (es) |
| EP (1) | EP2726482B1 (es) |
| JP (1) | JP5955953B2 (es) |
| KR (1) | KR20140036269A (es) |
| CN (1) | CN103764657B (es) |
| AP (1) | AP3529A (es) |
| AR (1) | AR087017A1 (es) |
| AU (1) | AU2012280508A1 (es) |
| BR (1) | BR112014000049A2 (es) |
| CA (1) | CA2840518A1 (es) |
| CO (1) | CO6870031A2 (es) |
| CU (1) | CU20130170A7 (es) |
| DO (1) | DOP2013000300A (es) |
| EA (1) | EA023775B1 (es) |
| EC (1) | ECSP13013120A (es) |
| ES (1) | ES2598027T3 (es) |
| GT (1) | GT201300313A (es) |
| IL (1) | IL229533A0 (es) |
| MA (1) | MA35601B1 (es) |
| MX (1) | MX2013014315A (es) |
| PE (1) | PE20140570A1 (es) |
| PH (1) | PH12013502695A1 (es) |
| SG (1) | SG195100A1 (es) |
| UY (1) | UY34167A (es) |
| WO (1) | WO2013004551A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI577670B (zh) | 2011-05-10 | 2017-04-11 | 基利科學股份有限公司 | 充當離子通道調節劑之稠合雜環化合物 |
| NO3175985T3 (es) | 2011-07-01 | 2018-04-28 | ||
| TWI622583B (zh) | 2011-07-01 | 2018-05-01 | 基利科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
| EP2809673B1 (en) * | 2012-01-31 | 2016-11-02 | Nanjing Allgen Pharma Co. Ltd. | Spirocyclic molecules as bruton's tyrosine kinase inhibitors |
| CA2945149A1 (en) * | 2014-04-10 | 2015-10-15 | Lankenau Institute For Medical Research | Methods and compositions for the treatment of ocular diseases and disorders |
| MX382659B (es) | 2014-05-28 | 2025-03-11 | Bayer Cropscience Ag | Proceso para la preparación de derivados de tiazol. |
| US10214537B2 (en) | 2014-10-22 | 2019-02-26 | Bristol-Myers Squibb Company | Bicyclic heteroaryl amine compounds |
| US10023576B2 (en) | 2014-10-22 | 2018-07-17 | Bristol-Myers Squibb Company | Heteroaryl substituted pyrrolotriazine amine compounds as PI3K inhibitors |
| CA2968464A1 (en) | 2014-11-25 | 2016-06-02 | Bayer Pharma Aktiengesellschaft | Substituted pyridobenzodiazepinone-derivatives and use thereof |
| EP3283475B1 (en) | 2015-04-16 | 2019-10-16 | Merck Patent GmbH | 3-(1h-benzimidazol-2-yl)-1h-pyridin-2-one derivatives |
| US10053465B2 (en) | 2015-08-26 | 2018-08-21 | Incyte Corporation | Pyrrolopyrimidine derivatives as TAM inhibitors |
| TWI753892B (zh) | 2016-03-28 | 2022-02-01 | 美商英塞特公司 | 作為ｔａｍ抑制劑之吡咯并三嗪化合物 |
| CN109111447A (zh) * | 2017-06-23 | 2019-01-01 | 中国科学院上海药物研究所 | 7-位取代吡咯并三嗪类化合物或其药学上可用的盐，及其制备方法和用途 |
| MA50655B1 (fr) | 2017-09-27 | 2021-11-30 | Incyte Corp | Sels de dérivés de pyrrolotriazine utiles en tant qu'inhibiteurs de tam |
| MD3813800T2 (ro) | 2018-06-29 | 2025-10-31 | Incyte Corp | Formulări de inhibitor al AXL/MER |
| CN115697343A (zh) | 2020-03-06 | 2023-02-03 | 因赛特公司 | 包含axl/mer和pd-1/pd-l1抑制剂的组合疗法 |
| CN120530116A (zh) | 2022-11-04 | 2025-08-22 | 百时美施贵宝公司 | Ret-ldd蛋白抑制剂 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2373990C (en) * | 1999-05-21 | 2007-05-08 | Bristol-Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
| CA2494179C (en) | 2002-08-08 | 2012-04-24 | Kissei Pharmaceutical Co., Ltd. | Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof |
| US7148226B2 (en) | 2003-02-21 | 2006-12-12 | Agouron Pharmaceuticals, Inc. | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same |
| UY28931A1 (es) | 2004-06-03 | 2005-12-30 | Bayer Pharmaceuticals Corp | Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis |
| DE102005042742A1 (de) * | 2005-09-02 | 2007-03-08 | Schering Ag | Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
| JP5116687B2 (ja) * | 2005-11-02 | 2013-01-09 | バイエル・ファルマ・アクチェンゲゼルシャフト | がんおよび他の過剰増殖性疾患の処置のためのピロロ［２，１−ｆ］［１，２，４］トリアジン−４−イルアミンＩＧＦ−１Ｒキナーゼ阻害剤 |
| US7514435B2 (en) * | 2005-11-18 | 2009-04-07 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| BRPI0619146A2 (pt) | 2005-12-02 | 2011-09-13 | Bayer Pharmaceuticals Corp | derivados de 4-amino-pirroltriazina substituìda úteis no tratamento de disordens e doenças hiperproliferativas associadas com angiogênesis |
| PE20070855A1 (es) | 2005-12-02 | 2007-10-14 | Bayer Pharmaceuticals Corp | Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas |
| CA2635231C (en) | 2005-12-29 | 2014-07-15 | Abbott Laboratories | Protein kinase inhibitors |
| EP1873157A1 (en) * | 2006-06-21 | 2008-01-02 | Bayer Schering Pharma Aktiengesellschaft | Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
| CN101522682A (zh) * | 2006-10-30 | 2009-09-02 | 诺瓦提斯公司 | 作为抗炎剂的杂环化合物 |
| PL2114980T3 (pl) | 2007-01-12 | 2012-11-30 | Biocryst Pharm Inc | Przeciwwirusowe analogi nukleozydów |
| US8124759B2 (en) | 2007-05-09 | 2012-02-28 | Abbott Laboratories | Inhibitors of protein kinases |
| ES2375425T3 (es) * | 2007-07-26 | 2012-02-29 | Novartis Ag | Compuestos org�?nicos. |
| JP5456681B2 (ja) * | 2007-10-17 | 2014-04-02 | ノバルティス アーゲー | ＡＬＫ阻害剤として有用なイミダゾ［１，２−ａ］ピリジン誘導体 |
| EP2300469B1 (en) * | 2008-05-13 | 2015-06-24 | Novartis AG | Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors |
| JP5656976B2 (ja) | 2009-04-29 | 2015-01-21 | ローカス ファーマシューティカルズ インコーポレイテッド | ピロロトリアジン化合物 |
-
2012
- 2012-06-26 BR BR112014000049A patent/BR112014000049A2/pt not_active IP Right Cessation
- 2012-06-26 CA CA2840518A patent/CA2840518A1/en not_active Abandoned
- 2012-06-26 EA EA201490103A patent/EA023775B1/ru not_active IP Right Cessation
- 2012-06-26 SG SG2013086426A patent/SG195100A1/en unknown
- 2012-06-26 AU AU2012280508A patent/AU2012280508A1/en not_active Abandoned
- 2012-06-26 PH PH1/2013/502695A patent/PH12013502695A1/en unknown
- 2012-06-26 ES ES12730515.9T patent/ES2598027T3/es active Active
- 2012-06-26 CN CN201280042804.7A patent/CN103764657B/zh not_active Expired - Fee Related
- 2012-06-26 WO PCT/EP2012/062366 patent/WO2013004551A1/en not_active Ceased
- 2012-06-26 JP JP2014517662A patent/JP5955953B2/ja not_active Expired - Fee Related
- 2012-06-26 MX MX2013014315A patent/MX2013014315A/es unknown
- 2012-06-26 KR KR1020137034741A patent/KR20140036269A/ko not_active Withdrawn
- 2012-06-26 US US14/130,586 patent/US9040691B2/en not_active Expired - Fee Related
- 2012-06-26 EP EP12730515.9A patent/EP2726482B1/en active Active
- 2012-06-26 AP AP2014007378A patent/AP3529A/xx active
- 2012-06-26 PE PE2013002774A patent/PE20140570A1/es not_active Application Discontinuation
- 2012-06-27 UY UY0001034167A patent/UY34167A/es not_active Application Discontinuation
- 2012-06-29 AR ARP120102378A patent/AR087017A1/es unknown
-
2013
- 2013-11-21 IL IL229533A patent/IL229533A0/en unknown
- 2013-12-05 CO CO13285797A patent/CO6870031A2/es active IP Right Grant
- 2013-12-11 DO DO2013000300A patent/DOP2013000300A/es unknown
- 2013-12-19 GT GT201300313A patent/GT201300313A/es unknown
- 2013-12-27 EC ECSP13013120 patent/ECSP13013120A/es unknown
- 2013-12-27 MA MA36620A patent/MA35601B1/fr unknown
- 2013-12-30 CU CUP2013000170A patent/CU20130170A7/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| AP2014007378A0 (en) | 2014-01-31 |
| CA2840518A1 (en) | 2013-01-10 |
| GT201300313A (es) | 2014-11-13 |
| EP2726482A1 (en) | 2014-05-07 |
| AP3529A (en) | 2016-01-11 |
| IL229533A0 (en) | 2014-01-30 |
| CU24146B1 (es) | 2016-02-29 |
| EA201490103A1 (ru) | 2014-06-30 |
| JP5955953B2 (ja) | 2016-07-20 |
| CN103764657B (zh) | 2016-05-25 |
| AU2012280508A1 (en) | 2013-12-12 |
| MA35601B1 (fr) | 2014-11-01 |
| UY34167A (es) | 2013-01-31 |
| NZ619453A (en) | 2016-01-29 |
| BR112014000049A2 (pt) | 2017-02-07 |
| US9040691B2 (en) | 2015-05-26 |
| EP2726482B1 (en) | 2016-07-20 |
| JP2014525902A (ja) | 2014-10-02 |
| SG195100A1 (en) | 2013-12-30 |
| WO2013004551A1 (en) | 2013-01-10 |
| US20140256718A1 (en) | 2014-09-11 |
| CU20130170A7 (es) | 2014-04-24 |
| PH12013502695A1 (en) | 2019-06-14 |
| MX2013014315A (es) | 2014-01-31 |
| EA023775B1 (ru) | 2016-07-29 |
| DOP2013000300A (es) | 2014-02-28 |
| AR087017A1 (es) | 2014-02-05 |
| ECSP13013120A (es) | 2014-02-28 |
| ES2598027T3 (es) | 2017-01-24 |
| CO6870031A2 (es) | 2014-02-20 |
| CN103764657A (zh) | 2014-04-30 |
| KR20140036269A (ko) | 2014-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20140570A1 (es) | Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos | |
| PE20141686A1 (es) | Compuestos de piperazina alquilados como inhibidores de actividad btk | |
| PE20151001A1 (es) | Alcoxipirazoles como activadores de guanilato ciclasa soluble | |
| GEP201706699B (en) | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh | |
| PE20160540A1 (es) | Inhibidores de bromodominios | |
| PE20142340A1 (es) | Inhibidores de bromodominios | |
| MX348920B (es) | Derivados de 2-(fenil o pirid-3-il)aminopirimidina como moduladores de proteina cinasa 2 de repeticion rica en leucina (lrrk2) para el tratamiento de la enfermedad de parkinson. | |
| EA201790306A1 (ru) | 2-(морфолин-4-ил)-1,7-нафтиридины | |
| PE20121815A1 (es) | Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6 | |
| PH12013501754A1 (en) | Triazolopyridine compounds as pim kinase inhibitors | |
| AR087182A1 (es) | DERIVADOS DE INDOL SUSTITUIDOS COMO MODULADORES DE g SECRETASA | |
| PE20160844A1 (es) | Compuestos triciclicos como agentes anticancerigenos | |
| CO6561783A2 (es) | Inhibidores del virus flaviviridae | |
| NZ716420A (en) | Fused heterocyclic compounds as sodium channel modulators | |
| PH12016501581A1 (en) | Benzimidazol-2-amines as midh1 inhibitors | |
| RU2014122035A (ru) | Соединения с нематоцидной активностью | |
| PE20151601A1 (es) | Compuestos novedosos de pirimidina y piridina y su uso | |
| PE20211472A1 (es) | Derivados de 2-(feniloxi o feniltio)pirimidina como herbicidas | |
| PE20141167A1 (es) | Piridopirazinas sustituidas como inhibidores novedosos de ptk | |
| CU20130126A7 (es) | Inhibidores sustituidos de acetil-coa carboxilasa | |
| JO3115B1 (ar) | مركبات بيريدازينون واستخدامها كمثبطات daao | |
| UY34480A (es) | Compuestos de 2-(fenilo sustituido)-ciclopentan-1,3-diona y derivados de los mismos, composiciones y métodos para controlar malezas. | |
| UY31973A (es) | Derivados de indol macrocíclicos útiles como inhibidores del virus de la hepatitis c | |
| CO2019013786A2 (es) | Métodos y composiciones para reducir la inmunogenicidad de los receptores notch quiméricos | |
| UY35229A (es) | Compuestos de diona cíclica herbicidas, derivados de los mismos, métodos de control de malezas y composiciones de los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |